en.Wedoany.com Reported - Solengepras has shown early potential in treating Parkinson's disease (PD), particularly targeting often-overlooked non-motor symptoms. Although improvements in motor function were limited, Phase II trial data indicate the drug can enhance sleep quality and related symptoms.

According to GlobalData analysis, this progress reflects a growing industry focus on holistic disease management, with therapies targeting non-motor pathways potentially redefining treatment priorities for Parkinson's disease.

This randomized, placebo-controlled study involved previously untreated patients with early-stage Parkinson's disease who received 150 mg of Solengepras daily for 12 weeks. The primary motor endpoint (MDS-UPDRS Parts II and III) showed only modest improvement over placebo (difference of -0.73), but more pronounced effects were observed in non-motor domains.

Specifically, Solengepras improved the MDS-UPDRS Part I score (difference of -1.01 at week 12) and delivered consistent benefits in sleep-related measures, such as the MDS-UPDRS sleep component and the Epworth Sleepiness Scale score. Additionally, trends toward improvement were seen in autonomic symptoms and behavioral aspects, while cognition and mood remained largely stable.

Non-motor symptoms, such as sleep dysfunction, fatigue, and cognitive impairment, are considered key contributors to the burden of Parkinson's disease. Yet existing therapies, including levodopa and dopamine agonists, offer limited efficacy in these areas.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com